PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 10, 2012Circulation315 citationsOpen Access

Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure

View Full Paper
MGMichael R. GoldCTChristophe ThébaultCLCecilia Linde

Key Result

Cardiac resynchronization therapy in mild heart failure patients with LBBB reduced left ventricular end-systolic volume index more than in non-LBBB patients (25.3 vs 6.7 mL/m2).

Key Points

  • This research aims to evaluate how baseline QRS duration and morphology influence outcomes in cardiac resynchronization therapy for patients with mild heart failure.
  • Multicenter randomized trial involving 610 patients with mild heart failure.
  • Evaluated baseline and CRT-paced QRS durations and morphology via blinded core laboratories.
  • Measured changes in left ventricular end-systolic volume index and clinical composite scores.
  • Patients with LBBB showed a significant reduction in left ventricular end-systolic volume index (25.3 mL/m²; P<0.0001) compared to non-LBBB patients (6.7 mL/m²; P=0.18).
  • Odds ratio for clinical improvement in LBBB subjects was 0.530 (P=0.0034), whereas for non-LBBB it was 0.724 (P=0.21).
  • Each 10-millisecond increase in QRS duration was associated with an odds ratio of 0.831 for clinical score improvement (P<0.0001).

Study Design

Type

RCT (n=610)

Randomization

Randomized

Multicenter

Yes

Structured PICO

Do baseline QRS duration and LBBB morphology predict reverse remodeling and clinical improvement with CRT in patients with mild heart failure?

P
Population
610 patients with mild heart failure. Mean baseline QRS duration was 151±23 milliseconds, and 60.5% had left bundle-branch block (LBBB).
I
Intervention
Cardiac resynchronization therapy (CRT) in patients with LBBB or prolonged QRS duration
C
Comparator
Cardiac resynchronization therapy (CRT) in patients without LBBB or with shorter QRS duration
O
Outcome
Change in left ventricular end-systolic volume index (LVESVI) and clinical composite scorecomposite

LBBB morphology and longer QRS duration are strong predictors of reverse remodeling and clinical benefit from CRT in patients with mild heart failure.

Main Result

Absolute Event Rate: 25.3% vs 6.7%

p-value: p=<0.0001

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) decreases mortality, improves functional status, and induces reverse left ventricular remodeling in selected populations with heart failure. We aimed to assess the impact of baseline QRS duration and morphology and the change in QRS duration with pacing on CRT outcomes in mild heart failure. METHODS AND RESULTS: Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) was a multicenter randomized trial of CRT among 610 patients with mild heart failure. Baseline and CRT-paced QRS durations and baseline QRS morphology were evaluated by blinded core laboratories. The mean baseline QRS duration was 151±23 milliseconds, and 60.5% of subjects had left bundle-branch block (LBBB). Patients with LBBB experienced a 25.3-mL/m(2) mean reduction in left ventricular end-systolic volume index (P<0.0001), whereas non-LBBB patients had smaller decreases (6.7 mL/m(2); P=0.18). Baseline QRS duration was also a strong predictor of change in left ventricular end-systolic volume index with monotonic increases as QRS duration prolonged. Similarly, the clinical composite score improved with CRT for LBBB subjects (odds ratio, 0.530; P=0.0034) but not for non-LBBB subjects (odds ratio, 0.724; P=0.21). The association between clinical composite score and QRS duration was highly significant (odds ratio, 0.831 for each 10-millisecond increase in QRS duration; P<0.0001), with improved response at longer QRS durations. The change in QRS duration with CRT pacing was not an independent predictor of any outcomes after correction for baseline variables. CONCLUSION: REVERSE demonstrated that LBBB and QRS prolongation are markers of reverse remodeling and clinical benefit with CRT in mild heart failure. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00271154.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gold et al. (2012) conducted an RCT in Mild heart failure (n=610). Cardiac resynchronization therapy (CRT) vs. non-LBBB was evaluated on change in left ventricular end-systolic volume index (p=<0.0001). Cardiac resynchronization therapy in mild heart failure patients with LBBB reduced left ventricular end-systolic volume index more than in non-LBBB patients (25.3 vs 6.7 mL/m2).

synapsesocial.com/papers/6a08137aad370a6b44ddefe7https://doi.org/10.1161/circulationaha.112.097709
Ask AI
Helpful
Bookmark
Share
View Full Paper